Transcriptomic Biomarker Analysis – Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disorder that primarily affects movement and leads to a loss of motor function. Gene expression analysis helps identify early biomarkers, better understand the underlying mechanisms of neurodegeneration, and guide therapeutic strategies.

Genes Analyzed in Parkinson’s Disease

Our panel targets key biomarkers associated with neurodegeneration, brain inflammation, and dopamine regulation, including:

• SNCA (Alpha-synuclein) – Involved in Lewy body formation, a key pathological marker

• LRRK2 (Leucine-rich repeat kinase 2) – Frequently mutated in familial forms of Parkinson’s

• PARK7 (DJ-1) – Antioxidant protein involved in cellular protection

• PINK1 – Gene regulating mitophagy; its mutation is linked to familial Parkinson’s disease

• PRKN (Parkin) – Protein involved in the clearance of damaged mitochondria

• GBA (Glucocerebrosidase) – Mutation associated with an increased risk of developing Parkinson’s disease

Applications & Benefits

• Identification of at-risk individuals, including those with genetic predispositions

• Monitoring disease progression based on transcriptomic alterations

• Early biomarker discovery for pre-symptomatic diagnosis

• Evaluation of new therapeutic targets to slow neurodegeneration

Technologies Used

We use advanced methods for precise and sensitive analysis:

• RT-qPCR and RNA-seq (NGS) for transcriptomic profiling

• Nanostring and transcriptomic arrays for targeted biomarker evaluation

• Analysis of genes linked to mitochondrial function and oxidative stress management

Contact us at contact@genxmap.com for tailored research or clinical analysis on Parkinson’s disease!